Sweden's Xbrane Biopharma Q3 revenue jumps on strong Ximluci sales
Sweden's Xbrane Biopharma Q3 revenue jumps on strong Ximluci sales
Overview
Sweden biosimilar drug developer's Q3 revenue rose sharply, driven by Ximluci product sales
Q3 EBITDA loss narrowed compared to prior year
After quarter end, company received FDA approval for ranibizumab biosimilar candidate
Outlook
Company did not provide specific financial or operational guidance for future periods in its press release
Result Drivers
XIMLUCI SALES - Q3 revenue growth was almost entirely driven by increased product sales of Ximluci
OTHER OPERATING INCOME - Co reported higher other operating income in Q3 compared to prior year
R&D SPENDING - R&D costs decreased as a share of total operating costs in Q3
Company press release: ID:nMFN1wdDHD
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | SEK 54.80 mln | SEK 24 mln (1 Analyst) |
Q3 Loss Per Share |
| SEK 0.57 |
|
Q3 Net Loss |
| SEK 11.70 mln |
|
Q3 EBITDA |
| -SEK 6.60 mln |
|
Analyst Coverage
Wall Street's median 12-month price target for Xbrane Biopharma AB is SEK16.25, about 25% above its October 29 closing price of SEK13.00
Reuters Recommended Reads
Oct 28 - Sweden's Newbury Pharmaceuticals Q4 revenue more than doubles on new product launches
Oct 28 - Sweden's BioInvent Q3 net sales rise but loss narrows
Oct 27 - China's Hengrui Pharma nine-month profit rises on out-licensing gains
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)